Skip to main content

Table 2 Pregnancy outcome categorized by time of discontinuation of natalizumab

From: Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study

Outcome of pregnancy, n (%) Before conception (n = 73) First trimester (n = 275) Second trimester (n = 10) Third trimester (n = 1) Continued during pregnancy (n = 4) Total (N = 363)
Spontaneous abortions 0 32 (11.6) 0 0 0 32 (8.8)
Elective termination (fetal defects) 1 (1.4) 0 0 0 0 1 (0.3)
Elective termination (no fetal defects or unknown) 2 (2.7) 11 (4.0) 0 0 0 13 (3.6)
Stillbirths without fetal defects 1 (1.4) 0 0 0 0 1 (0.3)
Live birth with congenital anomaly 7 (9.6)a 22 (8.0)b 0 0 0 29 (8.0)
Live birth without congenital anomaly 62 (84.9)c 210 (76.4)a 10 (100) 1 (100) 4 (100) 287 (79.1)
  1. aIncludes 2 sets of twins
  2. bIncludes 1 set of twins
  3. cIncludes 3 sets of twins